Nano-formulated curcumin (Lipodisq (TM)) modulates the local inflammatory response, reduces glial scar and preserves the white matter after spinal cord injury in rats
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F19%3A00508402" target="_blank" >RIV/68378041:_____/19:00508402 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/19:10395499 RIV/00216208:11150/19:10395499 RIV/00179906:_____/19:10395499
Result on the web
<a href="https://www.sciencedirect.com/science/article/abs/pii/S0028390819301674?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S0028390819301674?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.neuropharm.2019.05.018" target="_blank" >10.1016/j.neuropharm.2019.05.018</a>
Alternative languages
Result language
angličtina
Original language name
Nano-formulated curcumin (Lipodisq (TM)) modulates the local inflammatory response, reduces glial scar and preserves the white matter after spinal cord injury in rats
Original language description
A highly water soluble, nano-formulated curcumin was used for the treatment of the experimental model of spinal cord injury (SCI) in rats. Nanocurcumin and a vehicle nanocarrier as a control, were delivered both locally, immediately after the spinal cord injury, and intraperitoneally during the 4 consecutive weeks after SCI. The efficacy of the treatment was assessed using behavioral tests, which were performed during the experiment, weekly for 9 weeks. The behavioral tests (BBB, flat beam test, rotarod, motoRater) revealed a significant improvement in the nanocurcumin treated group, compared to the nanocarrier control. An immunohistochemical analysis of the spinal cord tissue was performed at the end of the experiment and this proved a significant preservation of the white matter tissue, a reduced area of glial scaring and a higher amount of newly sprouted axons in the nanocurcumin treated group. The expression of endogenous genes (Sort1, Fgf2, Irf5, Mrc1, Olig2, Casp3, Gap43, Gfap, Vegf, Nfk beta) and interleukins(IL-1 beta, TNF-alpha, IL-6, IL-12, CCL-5, IL-11, IL-10, IL-13) was evaluated by qPCR and showed changes in the expression of the inflammatory cytokines in the first two weeks after SCI.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Neuropharmacology
ISSN
0028-3908
e-ISSN
—
Volume of the periodical
155
Issue of the periodical within the volume
sep.
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
11
Pages from-to
54-64
UT code for WoS article
000474313900006
EID of the result in the Scopus database
2-s2.0-85066440987